Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Tarsus Pharmaceuticals (TARS) stock in plain English

Free brief · no signupStart here
TARSPublished Nov 18, 2026
Tarsus Pharmaceuticals Inc
Healthcare · Biotechnology
Produces and sells FDA-approved prescription eye drops that directly treat Demodex blepharitis by eliminating parasitic mites.
Assets:
Xdemvy eye dropsFirst FDA-approved prescription treatment for Demodex blepharitis
Headquarters in IrvineCentral operations based in the Southern California biotech corridor
Commercial sales teamDedicated specialty ophthalmic field force deployed across the United States
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

48
OPS ScoreOperating finances
Latest quote
+2.26%$77.67
$3.83B
n/a (loss)
$682.63M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was TARS. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Tarsus Pharmaceuticals (TARS) do?

Tarsus Pharmaceuticals Inc (TARS) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Produces and sells FDA-approved prescription eye drops that directly treat Demodex blepharitis by eliminating parasitic mites. Focuses on commercializing targeted treatments for eye diseases caused by Demodex mite infestations. It is worth $3.83B on the market and sold $682.63M over the last year.

Market cap
$3.83B
P/E ratio
None (reported a loss)
Annual sales
$682.63M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 18, 2026

Brands and businesses behind TARS

  • Xdemvy: Prescription eye drops sold through pharmacies to treat eyelid inflammation caused by Demodex mites.

TARS’s flags, in plain English

Each flag is a number from Tarsus Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Wide Gross Margin

Gross margin of 93.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Stupid Cash

Can pay this year's bills 2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Insiders Hold

Insiders own 5.4% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Burning Cash

Losing money, profit margin of -102.9%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more risk note open with the free trial. Try it free for 7 days.

Questions about TARS

How big is Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals’ market cap is $3.83B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $682.63M: what customers paid the company over the last year, before any costs.

What is TARS’s P/E ratio?

TARS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with TARS?

The business relies almost entirely on commercial sales of a single approved prescription product, Xdemvy. That is one risk on Tarsus Pharmaceuticals’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Tarsus Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TARS’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card